Tokai’s prostate can­cer drug im­plodes in PhI­II de­ba­cle

Just short of two years af­ter Boston-based Tokai Phar­ma­ceu­ti­cals $TKAI raised $97 mil­lion in an IPO, the small-cap biotech says its lead drug has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA